Email

The Prostate Cancer Test Is a Greed-Fueled Disaster

0 | By Michael A. Robinson

Here’s a personal statement that might shock you: I steadfastly refuse to get a prostate specific antigen (PSA) blood test to screen for prostate cancer.

It’s not because, as a baby boomer “of a certain age,” I don’t take the threat of prostate cancer seriously.

Far from it.

I know that prostate cancer kills an American male every 18 minutes on average each day, all year long. Prostate cancer is the No. 1 cancer risk – more than brain, skin, or lung cancer – for American men over 50.

And I pay a lot of attention to my health.

So a few years back I did extensive research on prostrate problems and solutions. It quickly became quite clear the risk of a getting a PSA was much, much worse than not getting one.

Here’s why I say that. Every year, about 30 million American men take a PSA test. That test measures the presence of prostate-specific antigens circulating in your bloodstream. Problem is, the PSA test is nothing more than a profit-driven health disaster that does NOT detect prostate cancer itself.

In fact, the PSA “fail rate” can be as high as 80%, according to Dr. Steven Salzberg, professor of biomedical engineering, computer scienc,e and biostatistics at Johns Hopkins University.

Even Dr. Richard Ablin, professor of pathology at the University of Arizona Cancer Center, the physician who developed the test back in 1970, now concedes the PSA test is a disaster pushed by pharmaceutical companies in search of profits. He compared its efficacy rate to that of a coin toss.

He even wrote a book about it, titled The Great Prostate Hoax: How Big Medicine Hijacked the PSA Test and Caused a Public Health Disaster.

And if you’re one of the unlucky ones… or if one of your loved ones receive a false positive… the consequences can be devastating. That’s because a false positive can lead to unnecessary surgeries that can leave men incontinent and impotent. Even getting a biopsy due to a false positive is potentially dangerous.

But here’s the good news in all of this…

My colleague, Ernie Tremblay, the Chief Scientific Researcher here at Money Morning, has researched a tiny $7-per-share company that’s developed a noninvasive breakthrough solution that could protect 50 million American men from the ravages of prostate cancer.

Ernie has carefully laid out some of the details of this firm and its revolutionary new prostate cancer test in a presentation you can view here. See, this small firm’s revolutionary diagnostic test spots prostate cancer at the molecular level, even in its earliest stages, when it’s easier to treat.

And unlike the PSA, this test has a mind-blowing 94% accuracy rate.

But timing is critical here. This tiny firm is only weeks, perhaps just days away from releasing critical Phase 3 trial results. Those results will be out by Sept. 30, 2018, at the latest!

This company could very well see a massive 72,500% sales surge.

For Ernie’s full presentation, click here.

You’re going to want to see this…

After battling with my doctors for years about this, I know I wanted to.

Cheers and good investing,


Michael A. Robinson

Leave a Reply

Your email address will not be published. Required fields are marked *